Market revenue in 2023 | USD 811.3 million |
Market revenue in 2030 | USD 1,642.0 million |
Growth rate | 10.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | BD, Danaher Corp, Koninklijke Philips NV, Qiagen NV, Thermo Fisher Scientific Inc, Myriad Genetics Inc, Argon Medical Devices, Roche Holding AG ADR, Hologic Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.93% in 2023. Horizon Databook has segmented the China breast cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
China is expected to grow at a lucrative CAGR over the forecast owing to increasing healthcare spending capacity in China, contributing to the fast growth of the market. Moreover, with growing population, individuals are more prone to chronic diseases, which further leads to increase in the growth of the market.
In addition, economic development and growth in disposable income are also among factors anticipated to boost the market for breast cancer treatment. According to the data published by the WHO in 2018, approximately 367,900 new cases of breast cancer were observed in this country, and it is one of the leading cancer types among women in the country.
The government also runs screening programs across China to ensure cost-effectiveness of screening in high-risk women. Increasing initiatives pertaining to raising awareness about breast cancer are expected to drive the market over the forecast period. For instance, Roche also conducts its Run for Her program in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China breast cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China breast cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account